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Abstract
Objectives. To investigate the frequency of anti-infliximab antibodies in patients with RA and the
associations with adverse drug reactions and treatment failure.
Methods. Based on the DANBIO registry, patients with RA who initiated treatment with infliximab at
Hvidovre Hospital between 2000 and 2008 and had available serum samples were identified. The patients
were followed for 52 weeks. Anti-infliximab antibodies were determined prior to infusion at baseline and
during follow-up (weeks 2, 6, 14 and 52 or at withdrawal) using the IMPACT indirect assay
(Roche Diagnostics) and merged with clinical data prospectively registered in the DANBIO registry.
Results. A total of 218 patients with RA were included (80% females, median age 56 years, disease
duration 10 years, 65% RF positive, median DAS28 = 5.0). During the 52-week follow-up, 28 patients
(13%) withdrew due to adverse events and 50 (23%) due to treatment failure. Antibodies were detected
in 118 patients (54%) during follow-up. Patients with detectable anti-infliximab antibodies after 6 weeks
had an increased risk of adverse drug reactions [hazard ratio (HR) = 5.06, 95% CI 2.36, 10.84; P< 0.0001]
compared with patients without anti-infliximab antibodies. Similar results were observed in patients with
anti-infliximab antibodies after 14 weeks (HR = 3.30, 95% CI 1.56, 6.99; P= 0.0009). Patients with detect-
able anti-infliximab antibodies during the 52-week follow-up were less likely to achieve sustained minimal
disease activity and remission.
Conclusion. Early anti-infliximab antibody formation increased the risk of adverse drug reactions, includ-
ing infusion reactions. Anti-infliximab antibody formation during the 52-week follow-up decreased the
likelihood of minimal disease activity and remission in patients with RA treated in routine care.
Key words: adverse drug reactions, anti-TNF therapy, DANBIO registry, drug response, infliximab, neutralizing
antibodies, pharmacological biomarkers, rheumatoid arthritis, treatment failure.
Introduction
TNF inhibitors have dramatically improved the outcome of
patients with RA [13]. However, response is variable and
at least 30% of patients with RA do not respond or lose
their initial response over time [4, 5]. Adverse drug reac-
tions, including infusion reactions, are common during
treatment with TNF inhibitors [4, 6, 7]. Immunogenicity is
a potential risk of protein drugs, and antidrug antibodies
(ADAs) against TNF inhibitors have been reported in
patients with RA, psoriasis, AS and Crohn’s disease
(CD) [713]. ADAs against TNF inhibitors are associated
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with a low level of active drug and treatment response in
patients with RA [8, 10, 1416]. However, ADAs are not
detected in all patients with treatment failure [7, 9]. This
suggests that treatment failure is a heterogeneous event
and only partly caused by ADAs against TNF inhibitors
[16, 17].
Little is known about the role of ADAs in relation to the
development of adverse drug reactions and whether the
presence of ADAs may predict serious adverse drug
reactions. A higher incidence of adverse drug reactions
has been reported in patients with RA, AS and CD with
ADAs against TNF inhibitors compared with patients with-
out ADAs [7, 12, 18, 19]. However, data are limited and it
is still debated whether and how to apply ADA measure-
ments in clinical practice. The frequency of ADAs against
TNF inhibitors varies because different assays have differ-
ent sensitivity, and the need for a sensitive assay has been
stressed [15, 17, 20].
In the present study, we measured the development of
anti-infliximab antibodies by a new, sensitive assay and
investigated the association between the presence of
antibodies and the development of negative clinical out-
comes, i.e. adverse drug reactions and treatment failure,
in patients with RA treated in routine care.
Patients and methods
Patients
Based on data from the Danish nationwide DANBIO reg-
istry, we identified 218 patients fulfilling the 1987 ACR
criteria for RA [21] who initiated treatment with infliximab
at Copenhagen University Hospital, Hvidovre, between
October 1999 and August 2008. DANBIO is a Danish na-
tionwide registry that prospectively collects clinical data
on patients with inflammatory rheumatic joint diseases [4,
22]. All patients included in the study were TNF naı¨ve and
had available serum samples drawn at baseline.
Treatment with infliximab was initiated in patients with
continuously active disease indicated by a DAS in 28
joints (DAS28) >3.2 or progression of radiographic joint
damage despite treatment with at least two different
DMARDs including MTX. Serum samples for
anti-infliximab antibody analysis were collected prior to
infusion on the day of treatment start (baseline) (n= 218)
and at weeks 2 (n= 167), 6 (n= 172), 14 (n= 180) and 52
(n= 128), or when the treatment was terminated (n= 34).
All patients were treated with infliximab 3 mg/kg at base-
line, weeks 2 and 6 and then every 8 weeks. The treating
rheumatologist was allowed to change dose according to
local guidelines; however, no patients received a dose
increase of infliximab before week 14.
Clinical response to infliximab
Clinical assessments were performed at baseline, at
weeks 2 and 6 and then every 8 weeks. Clinical evalu-
ation, registered prospectively and independently in
DANBIO, included tender and swollen joint counts (28
joints), visual analogue scale scores of pain, patient
global and physician global, HAQ, serum CRP and
DAS28 based on four variables including serum CRP [23].
Using the EULAR response criteria, patients were allocated
to one of the following outcomes: primary responders (con-
tinued EULAR good or moderate response), primary non-
responders (continued EULAR no response) and second-
ary non-responders (decrease in EULAR response after
initial EULAR good or moderate response at week 14).
Sustained minimal disease activity and sustained remis-
sion were defined according to Bartelds et al. [16] as a
DAS28 of < 3.2 or 2.6, respectively, at all consecutive
visits after a certain time point, with a minimum of two
measurements of < 3.2 or 2.6 in patients who withdrew
prematurely. To define anti-infliximab antibody status at
week 52, we used the visit closest to week 52 within the
time interval 4460 weeks. If no visit had occurred, the
latest visit during the first 43 weeks was selected. In case
of treatment withdrawal, the date and reasons were regis-
tered by the treating rheumatologist. This included treat-
ment failure, adverse drug reactions or other reasons
(which cover other known or unknown reasons).
Withdrawal due to adverse drug reactions was defined as
any adverse event leading to withdrawal of infliximab treat-
ment. Infusion reactions were defined as reactions occur-
ring during infusion, including skin rash, respiratory
symptoms, decrease in systemic blood pressure and
need for close monitoring. If withdrawal was due to a com-
bination of treatment failure and adverse drug reactions,
the case was classified as an adverse drug reaction.
The study was performed according to the Declaration
of Helsinki and written informed consent was obtained
from all patients. The study was approved by the Ethical
Committee of the Capital Region (Copenhagen), Denmark.
Multiplex automated assay for measurement of
antidrug antibodies
We used the multiplex platform IMPACT (Immunological
Multi-Parameter Chip Technology), developed by Roche
Professional Diagnostics (Roche Diagnostics GmbH). The
IMPACT platform is based on a small polystyrene chip
that is coated with a streptavidin layer, onto which bio-
tinylated antibodies, proteins or peptides are spotted.
During the assay, the arrayed markers are probed with a
small volume (40 ml) of diluted sample and with a digox-
igenylated secondary monoclonal antibody. The second-
ary antibody is then detected by the addition of an
anti-digoxigenin antibody conjugated to a fluorescent
latex label. This label enables highly sensitive detection
of <10 individual binding events in a single spot, down
to a fmol/l concentration. After a final incubation, chips
are transferred to a detection unit where a charge-coupled
device camera creates an image that is converted to
signal intensities, and fluorescence intensity of the array
features is quantified by image analysis.
In the present study, we developed an assay for the
determination of anti-infliximab antibodies. For that pur-
pose, infliximab was used as a biotinylated Fab fragment
and spotted onto the streptavidin-coated surface of the
chip. Patient samples were diluted 1:50 in a specific dilu-
tion buffer and each chip was probed with 40 ml of a
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diluted patient sample. In order to minimize interference,
the buffer contained interference minimizing substances,
among them Fab-poly antibodies. After a washing step,
each chip was probed with 40 ml of a digoxigenylated
mouse monoclonal IgG antibody. A serial dilution of
rabbit polyclonal anti-infliximab antibody was used as a
standard. The lower detection limit of the indirect assay
was determined at 0.27 ng/ml. A preliminary cut-off for the
assay was determined using 100 blood donor samples
and 218 baseline samples from the Copenhagen cohort.
A sample was considered positive if the signal was at least
2-fold above the highest signal seen in any blood donor or
baseline sample, otherwise as negative. This preliminary
cut-off was 75 ng/ml.
We determined inter-assay coefficient variation (CV) by
measuring three samples with low (4.3 ng/ml), medium
(87.4 ng/ml) and high (246.3 ng/ml) anti-infliximab antibody
levels, respectively, in six independent runs on different
days. Intra-assay CV was determined in samples with low
(4.3 ng/ml), medium (87.4 ng/ml) and high (246.3 ng/ml)
anti-infliximab antibody levels each measured 21 times.
We determined the functional sensitivity, defined as the
level corresponding to 20% inter-assay CV in five samples
spiked with calibrator material (polyclonal rabbit antibo-
dies fused to human IgG) measured in five independent
runs. The accuracy was determined in nine different donor
serum samples and horse serum samples by measuring
the recoveries of a fixed amount of either strongly positive
sample or a fixed amount of calibrator material (polyclonal
rabbit antibodies fused to human IgG). The recovery of
spiked analyte was calculated considering the intrinsic
anti-infliximab antibody level of each sample, which was
close to 0 for all samples (range 00.1 ng/ml). We deter-
mined the functional sensitivity in five samples spiked with
calibrator material (polyclonal rabbit antibodies fused to
human IgG) measured in five independent runs.
Infliximab interference was tested in 30 samples selected
according to anti-infliximab antibody level. Samples were
grouped into weak positive (<150 ng/ml), medium positive
(1502000 ng/ml) and strongly positive (>2000 ng/ml).
Each sample was spiked with 0, 1, 100 and 100mg/ml
infliximab, respectively. IgM and IgG RF interference
was tested in 146 IgM RF-positive (IgM> 20 U/ml) base-
line samples from the Copenhagen cohort.
Infliximab trough levels
Serum infliximab trough levels were measured at baseline,
week 14 and week 52 or when infliximab treatment was
terminated. All samples were measured at Biomonitor
ApS using RIA (Biomonitor ApS, Denmark), as previously
described [8].
Statistical analysis
Descriptive statistics for continuous variables are pre-
sented as medians and range. Categorical variables are
presented as frequencies and percentages. Patients were
dichotomized into patients with detectable anti-infliximab
antibodies and patients without detectable anti-infliximab
antibodies using the cut-off level of 75 ng/ml. In addition,
patients were classified using the EULAR response clas-
sification, the sustained low disease activity definition
(DAS28< 3.2) and the sustained remission definition
(DAS28< 2.6), respectively [16]. Differences between
groups were analysed using 2 or MannWhitney U stat-
istics as appropriate. The threshold for significance was
set at a two-sided P-value <0.05. KaplanMeier plots
were used to estimate the probability of drug survival,
sustained low disease activity and sustained remission.
Drug survival in patients with detectable anti-infliximab
antibodies after 6 weeks and 14 weeks of treatment
were compared with drug survival in patients without de-
tectable anti-infliximab antibodies using log-rank statistics
and hazard ratio (HR). Sustained low disease activity and
sustained remission in patients with detectable anti-
infliximab antibodies at week 52 were compared with sus-
tained low disease activity and sustained remission in
patients without detectable anti-infliximab antibodies
using log-rank statistics and HR. All data were analysed
using PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).
P-values <0.05 were considered significant.
Results
IMPACT assay
Inter- and intra-assay CV were 11.2% and 6.4%, respect-
ively. The functional sensitivity was 2.4 ng/ml. Recoveries
were within a range of ±12% with one exception (17%). In
spiking experiments of infliximab interference, weakly
positive anti-infliximab antibody samples showed border-
line/negative assay results starting from 10 mg/ml inflixi-
mab, while medium and strongly positive anti-infliximab
antibody samples showed borderline/negative assay re-
sults starting from 1000 mg/ml infliximab. Spiking with
100mg/ml infliximab showed a positive assay result in
nearly all samples classified as medium or strongly posi-
tive. The IgM RF interference test showed slightly elevated
unspecific signals between 80 and 194 counts, corres-
ponding to 3.311.2 ng/ml anti-infliximab antibodies in 4
of 146 IgM RF-positive baseline samples. All other sam-
ples showed signals below 40 counts, corresponding to
1.8 ng/ml anti-infliximab antibodies. The distribution of the
signals did not differ between IgM RF-positive patients
and IgM RF-negative patients, therefore the elevated sig-
nals in the four samples was due to non-specific binding
rather than to specific IgM RF interference. Similarly, no
IgG RF interference was observed. Supplementary Fig.
S1A, available at Rheumatology Online, shows a method
comparison experiment using 571 random serum samples
from the Copenhagen cohort of patients with RA. The
figure illustrates (shaded area) that several serum samples
with anti-infliximab antibody levels below the detection
limit when measured with a commercial assay [8] were
positive when measured with the IMPACT assay.
Baseline characteristics
Baseline characteristics of the 218 patients with RA are
given in Table 1. The majority of patients (80%) were
women with median age 56 years and a median disease
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duration 6 years, 65% were IgM RF positive and 56%
were anti-CCP antibody positive.
Anti-infiximab antibodies and infliximab trough levels
During the 52-week follow-up, anti-infliximab antibodies
were detected in a total of 118 patients (54%). After
6 weeks of treatment 39 of the 118 anti-infliximab
antibody-positive patients (33%) had detectable anti-
infliximab antibodies. After 14 weeks it was 79 of 118 pa-
tients (67%), while 92 of 118 patients (78%) had detect-
able anti-infliximab antibodies after 28 weeks of treatment
(supplementary Fig. S1B, available at Rheumatology
Online). After 14 weeks of treatment the median infliximab
trough level was 0.22mg/ml (range 0221.6mg/ml), while
the median infliximab trough level was 0.13 mg/ml (range
0135.7 mg/ml) after 52 weeks of treatment. Patients with
detectable anti-infliximab antibodies after 14 weeks of
treatment had lower median infliximab trough levels com-
pared with patients without detectable anti-infliximab anti-
bodies [0mg/ml (070.4mg/ml) vs 0.375 mg/ml (0221.6 mg/
ml), P< 0.001]. Similarly, patients with detectable anti-
infliximab antibodies after 52 weeks of treatment had
lower median infliximab trough levels compared with
patients without detectable anti-infliximab antibodies
[0mg/ml (07.40mg/ml) vs 0.29 mg/ml (0135.70 mg/ml),
P< 0.001] (supplementary Fig. 2, available at
Rheumatology Online).
Formation of anti-infliximab and risk of withdrawal
The time course of withdrawal is summarized in supple-
mentary Fig. S3, available at Rheumatology Online.
Overall, 136 patients completed 52 weeks of treatment,
while 82 patients withdrew. In the 50 patients (23%) who
withdrew due to treatment failure, the median DAS28 at
termination was 4.9 (IQR 4.355.56). When patients were
stratified according to anti-infliximab antibody status, 51
(43%) of the 118 anti-infliximab antibody-positive patients
withdrew during the 52-week follow-up due to treatment
failure (n= 30) and adverse drug reactions (n= 21). Of the
100 anti-infliximab antibody-negative patients, 31 (31%)
withdrew due to treatment failure (n= 20) and adverse
drug reactions (n= 7). The number of patients and reasons
for withdrawal during follow-up are summarized in Table 2
and supplementary Table S1, available at Rheumatology
Online. Patients with detectable anti-infliximab antibodies
during the 52-week follow-up had an increased risk of
adverse drug reactions compared with patients without
detectable anti-infliximab antibodies [21 (18%) vs 7
(7%), P< 0.018]. Patients with detectable anti-infliximab
antibodies during the 52-week follow-up had an increased
risk of infusion reactions [17 (14%) vs 0 (0%), P< 0.001].
Twelve of 17 patients (71%) who withdrew due to infusion
reactions had detectable anti-infliximab antibodies after 6
weeks of treatment. Patients with detectable anti-
infliximab antibodies after 6 weeks of treatment had an
increased risk of withdrawal due to adverse drug
TABLE 1 Baseline characteristics and clinical responses
Variable All Anti-infliximab AB+ Anti-infliximab AB
No. of patients 218 118 100
Demographics
Age, years 56 (2186) 56 (2186) 57 (2586)
Women 175 (80) 98 (83) 77 (77)
Disease duration 6 (056) 6 (056) 5 (047)
Ever smokersa 132 (65) 64 (68) 64 (62)
Glucocorticoids 53 (24) 25 (21) 28 (28)
MTX 181 (91) 95 (90) 86 (91)
MTX dose, mg/week 20 (025) 20 (025) 22.5 (025)
Laboratory values at baseline
IgM-RF positive 141 (65) 84 (71) 57 (57)
Anti-CCP positiveb 59 (53) 38 (58) 21 (46)
Serum CRP, mg/l 13 (3280) 14 (3280) 12 (476)
Disease activity measures at baseline
HAQ score (03) 1.250 (03.0) 1.250 (03.0) 1.375 (02.8)
Pain score (0100) 58 (2100) 61 (2100) 55 (3100)
Patient global score (0100) 62 (0100) 62 (2100) 62 (0100)
Physician’s global score (0100) 47 (095) 46 (095) 49 (095)
DAS28 5.0 (1.68.2) 5.0 (1.88.2) 5.0 (1.67.8)
Clinical response at week 14
DAS28 3.4 (2.24.6) 3.6 (1.77.6) 3.2 (1.67.3)
EULAR good responsec 32 (18) 15 (15) 17 (22)
EULAR moderate responsec 68 (39) 43 (44) 25 (33)
EULAR no responsec 74 (43) 40 (41) 34 (45)
Anti-infliximab AB+: patients with anti-infliximab antibodies during the 52-week follow-up. Anti-infliximab AB: patients without
anti-inflimixab antibodies during the 52-week follow-up. Values are given as median (range) or as number (percentage of total).
aSix patients had missing smoking data; b107 patients had missing anti-CCP values; c21 patients had missing clinical data.
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reactions during the 52-week follow-up compared with pa-
tients without anti-infliximab antibodies (HR = 5.06, 95% CI
2.36, 10.84; P< 0.0001) (Fig. 1A). Similar results were
found for patients with detectable anti-infliximab antibo-
dies after 14 weeks of treatment (HR = 3.30, 95% CI 1.56,
6.99; P= 0.0009) (Fig. 1C). There was no significant asso-
ciation between anti-infliximab antibody status after 6 and
14 weeks of treatment and withdrawal due to treatment
failure during the 52-week follow-up (Fig. 1B and D).
Formation of anti-infliximab antibodies and treatment
response
In this analysis, we included only patients with a DAS28
53.2 at baseline (n= 175 patients). In total, 64 (37%) pa-
tients were classified as primary responders, 67 (38%) pa-
tients as primary non-responders and 32 (19%) patients as
secondary non-responders. Twelve patients (6%) had only
one follow-up visit after initiation of infliximab. Secondary
non-responders had lower median serum infliximab trough
levels than primary non-responders [0 mg/ml (091.3mg/ml)
vs 0.215 mg/ml (0221.6mg/ml), P= 0.012]. There was no
difference in median serum infliximab levels between pri-
mary responders and primary/secondary non-responders
[0.155 mg/ml (0114mg/ml) vs 0.140 mg/ml (0221.6 mg/ml),
P= 0.548]. Of the 175 patients, 83 (47%) had detectable
anti-infliximab antibodies during the 52-week follow-up.
There was no difference in anti-infliximab antibody status
between patients classified as primary responders and pri-
mary non-responders [27 (42%) vs 30 (45%), P= 0.765].
Fewer primary responders had detectable anti-infliximab
antibodies in serum than secondary non-responders [27
(48%) vs 22 (69%), P= 0.014]. More patients with second-
ary non-response had detectable anti-infliximab antibo-
dies in serum than patients with primary non-response
[22 (69%) vs 30 (45%), P= 0.025]. Patients with detectable
anti-infliximab were less likely to achieve sustained min-
imal disease activity (DAS28<3.2) compared with patients
without detectable anti-infliximab antibodies (HR = 0.49,
95% CI 0.27, 0.92, P= 0.023) (Fig. 2A). Similarly, patients
with detectable anti-infliximab antibodies were less likely
to achieve sustained remission (DAS28< 2.6) compared
with patients without (HR = 0.53, 95% CI 0.28, 0.98;
P= 0.04) (Fig. 2B).
Discussion
To our knowledge, this is the first study demonstrating
that early formation of anti-infliximab antibodies increases
the risk of serious and potentially life-threatening adverse
drug reactions in patients with RA treated with TNF inhibi-
tors in clinical practice. Patients with detectable anti-
infliximab antibodies had lower median infliximab trough
levels and were less likely to achieve sustained minimal
disease activity and remission.
In accordance with previous studies [8, 10, 24], our
results showed that early formation of anti-infliximab anti-
bodies was common in patients with RA during infliximab
treatment despite concomitant MTX. In our study, only
IgM RF and glucocorticoid treatment at baseline differed
between patients with and without detectable anti-
infliximab antibodies. It is largely unknown why some pa-
tients develop ADAs against TNF inhibitors [24]. One study
reported that patients with detectable anti-infliximab anti-
bodies that switch to adalimumab are more prone to de-
velop anti-adalimumab antibodies than TNF-naı¨ve
patients, suggesting a genetic disposition [25]. This is
supported by a study that identified an association be-
tween IL-10 polymorphisms and increased formation of
anti-adalimumab antibodies in patients with RA treated
with adalimumab [26].
TABLE 2 Reason for withdrawal during the 52-week follow-up
No. (%) of patients
Total (n= 218) Anti-infliximab AB+ (n= 118) Anti-infliximab AB (n= 100)
Completed treatment 136 (62) 67 (57) 69 (69)
Withdrawn
Treatment failure 50 (23) 30 (25) 20 (20)
Adverse drug reaction 28 (13) 21 (18)a 7 (7)a
Infusion reaction 17 of 218 (8) 17 of 118 (14)b 0 of 100 (0)b
Urticaria 2 of 218 (1) 1 of 118 (1) 1 of 100 (1)
Infection 2 of 218 (1) 1 of 118 (1) 1 of 100 (1)
Exanthema 2 of 218 (1) 1 of 118 (1) 1 of 100 (1)
Polyneuropathia 1 of 218 (1) 0 of 118 (0) 1 of 100 (1)
Other 4 of 218 (2) 1 of 118 (1) 3 of 100 (3)
Other 4 (2) 0 (0) 4 (4)
Total withdrawn 82 (38) 51 (43) 31 (31)
Anti-infliximab AB+: patients with anti-infliximab antibodies during the 52-week follow-up. Anti-infliximab AB: patients without
anti-infliximab antibodies during the 52-week follow-up. aAnti-infliximab AB+ patients had an increased risk of adverse drug
reactions during the 52-week follow-up compared with patients without anti-infliximab antibodies (P< 0.018). bAnti-infliximab
AB+ patients had an increased risk of infusion reactions during the 52-week follow-up compared with patients without
anti-infliximab antibodies (P<0.001).
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ADAs have been suggested to cause adverse drug re-
actions, including anaphylactic reactions, during TNF in-
hibitor therapy, but data are limited [7, 27]. We found that
patients with detectable anti-infliximab antibodies after
either 6 or 14 weeks had an increased risk of adverse
drug reactions during the 52-week follow-up.
In a recent study by Bartelds et al. [16], patients with
detectable anti-adalimumab antibodies during the
156-week follow-up were less likely to achieve sustained
minimal disease activity and sustained remission com-
pared with patients without detectable anti-adalimumab
antibodies. This was also demonstrated in our study. In
contrast, we did not find any association between antibody
status and withdrawal due to treatment failure. Differences
between adalimumab and infliximab with regard to dosing
regimens, pharmacokinetic properties and immunogen-
icity might explain this lack of association. Intravenous
administration of infliximab results in high initial serum
levels and large fluctuations, whereas serum levels of
adalimumab are relatively constant and reach steady
state in 2 weeks. Another reason for lack of association
might be differences in outcome measures. In our study,
the decision to withdraw treatment was made by the treat-
ing physician, whereas sustained low disease activity and
remission are more objective criteria. Furthermore, inflixi-
mab treatment initiated during the first years of
post-marketing was less likely to be withdrawn by the clin-
icians due to the limited availability of alternative biologic
agents. The time of follow-up was longer in our study than
in the study by Bartelds et al. [16]. One may also hypothe-
size that differences between the two cohorts with regard
to treatment with glucocorticoids and DMARDs, erosive
disease and smoking status may, at least in part, explain
some of the differences between the two studies.
Patients with detectable anti-infliximab antibodies had
lower median infliximab trough levels compared with pa-
tients without detectable anti-infliximab antibodies.
However, a few patients had high infliximab trough
FIG. 1 Drug survival in relation to antibody status after 6 weeks and 14 weeks of treatment.
In (A) and (C), the reason for withdrawal was adverse drug reactions and patients withdrawn due to other reasons were
not included. In (B) and (D), the reason for withdrawal was treatment failure and patients withdrawn due to other reasons
were not included. AIA+: patients with detectable anti-infliximab antibodies. AIA: patients without detectable
anti-infliximab antibodies.
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levels despite being anti-infliximab antibody positive,
because they had blood samples drawn after infliximab
infusion. Patients with secondary non-response had
lower median infliximab levels in serum and more often
detectable anti-infliximab antibodies compared with pa-
tients with primary non-response. This supports the
hypothesis that secondary non-response is caused by
ADAs and that patients with primary non-response to
one TNF inhibitor are more likely to benefit from another
TNF inhibitor than to dosage escalation [17].
Different methods including ELISA and RIA can be used
to assess ADA in patients with RA treated with TNF inhibi-
tors [710, 15, 1820, 2831]. Some assays have poor
sensitivity, and interaction with non-specific immuno-
globulins or IgG RF and the active drug may generate
false-negative results [20, 2831]. In our study,
anti-infliximab antibodies were measured in 218 patients
with RA using a newly developed highly sensitive and fast
assay. No cross-reactivity or interference with rheumatoid
factors (IgG, IgA and IgM subclasses) was observed. In
spiking experiments, weakly positive samples showed
borderline/negative assay results starting from 10 mg/ml
infliximab. Thus the assay may underestimate the level
of anti-infliximab antibodies and hence the number of pa-
tients with a positive anti-infliximab antibody titre may ac-
tually be higher. Several publications report an infliximab
trough level of between 5 and 10 ml/ml. In weakly positive
serum samples, these levels would lead to false-negative
results using the IMPACT assay.
Some strengths of our study are the high sensitivity of
the IMPACT assay and the well-characterized patient
cohort comprising RA patients treated with infliximab.
Furthermore, all clinical variables were registered
prospectively in the DANBIO registry at each visit. Some
limitations must be taken into account when interpreting
the results. The patients in our study were heterogeneous
with regard to disease duration and disease severity.
Patients initiating infliximab treatment during the first
years of post-marketing use often had longer disease dur-
ation, more severe disease and more joint destruction
compared with patients initiating infliximab treatment in
2008. Patients with severe long-lasting disease might ex-
perience less benefit from treatment than RA patients with
shorter disease duration.
In conclusion, the present study of patients with RA
treated with infliximab in routine care demonstrated that
early formation of anti-infliximab antibodies increased the
risk of adverse drug reactions. Furthermore, patients with
detectable anti-infliximab antibody formation during 52
weeks were less likely to achieve sustained minimal dis-
ease activity and remission. Thus assessment of
anti-infliximab antibodies may support the identification
of patients who are likely to develop adverse drug reac-
tions and patients who are less likely to respond convin-
cingly to infliximab treatment.
Rheumatology key messages
. Early formation of anti-infliximab antibodies is
common in patients with RA treated with infliximab.
. Anti-infliximab antibodies increase the risk of
adverse drug reactions, including infusion reactions,
in RA patients.
. Anti-infliximab antibodies decrease the likelihood of
sustained minimal disease activity and remission in
RA patients.
FIG. 2 Sustained minimal disease activity and sustained remission.
Sustained minimal disease activity (A) and sustained remission (B) in patients classified according to anti-infliximab status
during the 52-week follow-up. AIA+: patients with detectable anti-infliximab antibodies. AIA: patients without detectable
anti-infliximab antibodies.
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